期刊文献+

微小RNA-34a在肝癌组织的表达及其临床意义 被引量:3

Expression of microRNA -341 in hepatocellular carcinomas and its significance
原文传递
导出
摘要 目的探讨微小RNA(miRNA,miR)-34a在肝癌组织中表达及其与临床病理特征的关系。方法应用实时定量聚合酶链反应(Real-timePCR)技术检测59例肝癌及其癌旁组织中miR-34a的表达量,并分析miR-34a在不同组织中的表达差异及其与肝癌临床病理特征间的关系,探讨miR-34a在肝癌发生与进展中的重要作用。结果肝癌组织中miR-34a的相对表达量(0.52±0.21)明显低于正常肝组织(5.57±1.48,P〈0.05),病理分级Ⅲ-Ⅳ级(0.32±0.12)和TNM分期Ⅲ-Ⅳ期(0.35±0.13)的肝癌患者组织中miR-34a的表达水平明显低于Ⅰ-Ⅱ级(0.69±0.22,0.72±0.19;P〈0.01)。结论miR-34a表达水平与肝癌发生发展及恶性程度密切相关。 Objective To investigate the clinicopathologic significance of microRNA (miRNA, miR) - 34a expression in hepatocellular carcinomas (HCC). Methods Real - time quantitative polymer- ase chain reaction ( Real - time PCR) was used to quantify miR - 34a expression in 59 pairs of HCC tis- sues and matched normal hepatic tissues. The association of miR - 34a expression with the clinicopatholog- ic features was evaluated. Results The expression of miR - 34a was significantly downregulated in HCC tissue samples (0. 52 ± 0. 21 ) compared to matched normal tissues (5.57 ± 1.48, P 〈 0. 05). MiR - 34a was highly expressed in HCC with a low pathological grade ( Ⅰ - Ⅱ: 0. 69±0. 22) but markedly decreased in grade (Ⅲ - Ⅳ : 0. 32 ±0. 12) tumors (P 〈0.01 ). In addition, there was significant difference in the expression of miR - 34a between patients with TNM stages Ⅰ - Ⅱ (0. 72 ± 0. 19 ) and those with stage Ⅲ - Ⅳ (0. 35 ± 0. 13 ) HCC ( P 〈 0. 01 ). Conclusion The expression of miR - 34a is closely relat- ed to the development and progression of HCC.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2016年第12期2759-2760,共2页 Chinese Journal of Experimental Surgery
基金 武汉市中心医院青年基金(YQ14A02)
关键词 微小RNA-34a 微小RNA 肝细胞 MicroRNA - 34a MicroRNA Carcinoma, hepatocellular
  • 相关文献

参考文献1

二级参考文献9

  • 1Bartel DP. MicroRNAs : genomics, biogenesis, mechanism, and function [ J ]. Cell ,2004,116 (2) :281-297.
  • 2Zhao G, Guo J, Li D et al. MicroRNA-34a suppresses ee proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line[J]. DNA Cell Bio1,2013,32(12) :699-707.
  • 3Li X J, Ren ZJ, Tang JH, et al. MicroRNA-34a : a potential therapeutic target in human cancer [J]. Cell Death Dis,2014,5 ( 7 ) : el 327.
  • 4Tivnan A, Orr WS, Gubala V, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using mati-disial~ganglio- side GD2 coated nanoparticles[ J]. PLoS One,2012,7(5 ) :e38129.
  • 5Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma:a systematic re- view of the literature [ J]. Crit Rev Oncol Hemato1,2014,91 (1) :I-8.
  • 6Wang ZG,Zhang GF,Wu JC ,et al. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect [ J]. Drug Discov Ther, 2013.7(4) :137-143.
  • 7Ghebeh H, A1-Khaldi S, 01abi S, et al. Fascin is involved in the che- motherapeutic resistance of breast cancer ceils predominantly via the PI3 K/Akt pathway [ J ]. Br J Cancer,2014,111 ( 8 ) : 1552-1561.
  • 8Luk SU,Xue H,Cheng H,et al. The BIRC6 gene as a novel target for therapy of prostate caneer : dual targeting of inhibitors of apoptosis [ J ~. Oneotarget,2014,5 (16) :6896-6908.
  • 9徐力致,余德才,王亚平,丁义涛.microRNA在肝细胞肝癌诊断和治疗中的研究进展[J].中华实验外科杂志,2010,27(2):271-272. 被引量:14

共引文献7

同被引文献26

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部